NorthWest Biotherapeutics Inc (NWBO)

[Roman516]

NWBO pressing onward and forward.

However bogus information
"The failure rate of Phase 3 trial for approvals is ~40%. The primary reason:
"The reasons for these failures appear to be unchanged: 75 to 80% are due to problems with efficacy and/or safety."

NWBO's questionable manipulated trial data, complete confounding of the naive OS, post hoc data dredged recurrent OS arm (n=64) -- Good luck boys."

The OS data results exceed expectations, the majority of the doctors, scientist, and professionals all agree that DCVax-L will be able to help many cancer patients and the results are proving this. NWBO is like back to the future where the flux capacitor helmet was tossed away. NWBO's OS results will pave the way to more effective cures as time moves forward.